Search Results

There are 13510 results for: content related to: The history of the development of buprenorphine as an addiction therapeutic

  1. FROM WHITE BULLETS TO BLACK MARKETS AND GREENED MEDICINE: THE NEUROECONOMICS AND NEURORACIAL POLITICS OF OPIOID PHARMACEUTICALS

    Annals of Anthropological Practice

    Volume 36, Issue 1, May 2012, Pages: 167–182, Helena Hansen and Mary E. Skinner

    Version of Record online : 19 SEP 2012, DOI: 10.1111/j.2153-9588.2012.01098.x

  2. You have free access to this content
    Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

    Intervention Review

    The Cochrane Library

    Richard P Mattick, Courtney Breen, Jo Kimber and Marina Davoli

    Published Online : 6 FEB 2014, DOI: 10.1002/14651858.CD002207.pub4

  3. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers

    Addiction

    Volume 105, Issue 4, April 2010, Pages: 709–718, Sandra D. Comer, Maria A. Sullivan, Suzanne K. Vosburg, Jeanne Manubay, Leslie Amass, Ziva D. Cooper, Phillip Saccone and Herbert D. Kleber

    Version of Record online : 10 MAR 2010, DOI: 10.1111/j.1360-0443.2009.02843.x

    Corrected by:

    Erratum

    Vol. 105, Issue 7, 1322, Version of Record online: 8 JUN 2010

  4. You have free access to this content
    AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT

    British Journal of Pharmacology

    Volume 60, Issue 4, August 1977, Pages: 537–545, A. COWAN, J.W. LEWIS and I.R. MACFARLANE

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1476-5381.1977.tb07532.x

  5. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users

    Addiction Biology

    Volume 20, Issue 4, July 2015, Pages: 784–798, Jermaine D. Jones, Maria A. Sullivan, Suzanne K. Vosburg, Jeanne M. Manubay, Shanthi Mogali, Verena Metz and Sandra D. Comer

    Version of Record online : 24 JUL 2014, DOI: 10.1111/adb.12163

  6. Correlations of Maternal Buprenorphine Dose, Buprenorphine, and Metabolite Concentrations in Meconium With Neonatal Outcomes

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 5, November 2008, Pages: 604–612, SL Kacinko, HE Jones, RE Johnson, RE Choo and MA Huestis

    Version of Record online : 13 AUG 2008, DOI: 10.1038/clpt.2008.156

  7. Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials

    The Journal of Clinical Pharmacology

    Volume 46, Issue 2, February 2006, Pages: 179–192, Dr Domenic A. Ciraulo, Dr Robert J. Hitzemann, Dr Eugene Somoza, Dr Clifford M. Knapp, Dr John Rotrosen, Dr Ofra Sarid-Segal, Ms Ann Marie Ciraulo, Dr David J. Greenblatt and Dr C. Nora Chiang

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005284192

  8. Opioid agonist treatment for pharmaceutical opioid dependent people

    Intervention Review

    The Cochrane Library

    Suzanne Nielsen, Briony Larance, Louisa Degenhardt, Linda Gowing, Chyanne Kehler and Nicholas Lintzeris

    Published Online : 9 MAY 2016, DOI: 10.1002/14651858.CD011117.pub2

  9. Compliance with Buprenorphine Medication-Assisted Treatment and Relapse to Opioid Use

    The American Journal on Addictions

    Volume 21, Issue 1, January-February 2012, Pages: 55–62, Joseph Tkacz, Jamie Severt, John Cacciola and Charles Ruetsch

    Version of Record online : 18 NOV 2011, DOI: 10.1111/j.1521-0391.2011.00186.x

  10. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers

    Addiction

    Volume 106, Issue 8, August 2011, Pages: 1460–1473, Lisa S. Middleton, Paul A. Nuzzo, Michelle R. Lofwall, David E. Moody and Sharon L. Walsh

    Version of Record online : 3 MAY 2011, DOI: 10.1111/j.1360-0443.2011.03424.x

  11. You have free access to this content
    Fetal assessment before and after dosing with buprenorphine or methadone

    Addiction

    Volume 107, Issue S1, November 2012, Pages: 36–44, Amy L. Salisbury, Mara G. Coyle, Kevin E. O'Grady, Sarah H. Heil, Peter R. Martin, Susan M. Stine, Karol Kaltenbach, Manfred Weninger and Hendrée E. Jones

    Version of Record online : 29 OCT 2012, DOI: 10.1111/j.1360-0443.2012.04037.x

  12. You have free access to this content
    Buprenorphine for treating cancer pain

    Intervention Review

    The Cochrane Library

    Mia Schmidt-Hansen, Nathan Bromham, Mark Taubert, Stephanie Arnold and Jennifer S Hilgart

    Published Online : 31 MAR 2015, DOI: 10.1002/14651858.CD009596.pub4

  13. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients

    Drug and Alcohol Review

    Volume 30, Issue 6, November 2011, Pages: 613–620, BRIONY LARANCE, LOUISA DEGENHARDT, SUSANNAH O'BRIEN, NICK LINTZERIS, ADAM WINSTOCK, RICHARD P. MATTICK, JAMES BELL and ROBERT ALI

    Version of Record online : 5 JAN 2011, DOI: 10.1111/j.1465-3362.2010.00274.x

  14. Opioid-related mortality and filled prescriptions for buprenorphine and methadone

    Drug and Alcohol Review

    Volume 33, Issue 5, September 2014, Pages: 491–498, Birgitta N. Wikner, Inger Öhman, Tor Seldén, Henrik Druid, Lena Brandt and Helle Kieler

    Version of Record online : 16 APR 2014, DOI: 10.1111/dar.12143

  15. You have free access to this content
    Steps Physicians Report Taking to Reduce Diversion of Buprenorphine

    The American Journal on Addictions

    Volume 22, Issue 3, May-June 2013, Pages: 184–187, Amy Yang, Cynthia L. Arfken and Chris-Ellyn Johanson

    Version of Record online : 25 APR 2013, DOI: 10.1111/j.1521-0391.2012.00335.x

  16. Buprenorphine

    Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants

    Donald G. Barceloux, Pages: 514–526, 2012

    Published Online : 2 FEB 2012, DOI: 10.1002/9781118105955.ch28

  17. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia

    Addiction

    Volume 110, Issue 4, April 2015, Pages: 646–655, Lucy Burns, Natasa Gisev, Sarah Larney, Timothy Dobbins, Amy Gibson, Jo Kimber, Briony Larance, Richard P. Mattick, Tony Butler and Louisa Degenhardt

    Version of Record online : 15 MAR 2015, DOI: 10.1111/add.12834

  18. You have free access to this content
    Maternal Opioid Treatment: Human Experimental Research (MOTHER)—approach, issues and lessons learned

    Addiction

    Volume 107, Issue S1, November 2012, Pages: 28–35, Hendrée E. Jones, Gabriele Fischer, Sarah H. Heil, Karol Kaltenbach, Peter R. Martin, Mara G. Coyle, Peter Selby, Susan M. Stine, Kevin E. O'Grady and Amelia M. Arria

    Version of Record online : 29 OCT 2012, DOI: 10.1111/j.1360-0443.2012.04036.x

  19. Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience

    The American Journal on Addictions

    Volume 13, Issue S1, May-June 2004, Pages: S42–S66, Leslie Amass, Walter Ling, Thomas E. Freese, Chris Reiber, Jeffrey J. Annon, Allan J. Cohen, Dennis McCarty, Malcolm S. Reid, Lawrence S. Brown Jr., Cynthia Clark, Douglas M. Ziedonis, Jonathan Krejci, Susan Stine, Theresa Winhusen, Greg Brigham, Dean Babcock, Joan A. Muir, Betty J. Buchan and Terry Horton

    Version of Record online : 18 FEB 2010, DOI: 10.1080/10550490490440807

  20. Improving Temporal Efficiency of Outpatient Buprenorphine Induction

    The American Journal on Addictions

    Volume 20, Issue 5, September-October 2011, Pages: 397–404, Erik W. Gunderson, Frances R. Levin, Margaret M. Rombone, Suzanne K. Vosburg and Herbert D. Kleber

    Version of Record online : 18 JUL 2011, DOI: 10.1111/j.1521-0391.2011.00153.x